Comment from Lonza

Summary: Lonza, a Contract Development and Manufacturing Organization (CDMO), supports the FDA's initiative to update the SUPAC guidances to align with modern science-based and risk-based approaches. They suggest incorporating specific guidance on co-processed excipients, modern manufacturing technologies, and packaging equipment to reduce regulatory uncertainty and improve lifecycle management.